Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CAROTID: CAD Randomized Omega-3 Trial In Depression
Brief Summary: Depressive disorders are common in patients with Coronary Artery Disease (CAD), occurring in up to 47% of patients. Left untreated, these symptoms not only have a strong negative impact on quality-of-life, but also increase risk of future cardiac events and death. Unfortunately, about 64% of CAD patients do not respond to current antidepressant treatments. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are two omega-3 (ω-3) fatty acids found in fatty fish that are important for brain function. Recent evidence showed that depressed CAD patients have lower levels of EPA and DHA than non-depressed CAD patients. This information, taken together with the known roles of ω-3 fatty acids in brain function, suggests that deficiencies may contribute to depression. However, it is unknown if increasing consumption of ω-3 fatty acids would alleviate depression and improve quality of life. While intake of adequate levels of ω-3 fatty acids is difficult to obtain through diet, concentrated supplements containing EPA and DHA that are safe, readily available, and inexpensive are now obtainable in Canada. CAROTID (CAD Randomized Omega-3 Trial In Depression) will randomize patients with CAD, with and without depressive symptoms, after 6 months of cardiac rehabilitation and usual care to receive either ω-3 fatty acid supplements or placebo daily during their final 6 months of cardiac rehabilitation. The investigators hypothesize that CAD patients randomized to receive ω-3 fatty acid supplements will show greater improvement in depressive symptoms and quality-of-life over time. The investigators will also evaluate possible improvements in other important determinants of quality of life: memory and other cognitive abilities.


Options:
A: Arm Label: Depressed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducation; Treatment recommendations, Drug: Pharmacotherapy | Arm Label: Depressed Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Arm Label: Non-Depressed Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducation; Treatment recommendations; Assigned to Arm(s): Depressed Intervention | Intervention Type: DRUG; Name: Pharmacotherapy; Assigned to Arm(s): Depressed Intervention | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Depressed Usual Care
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Supervised Aerobic Exercise | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sertraline | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Pill. | Intervention Type: BEHAVIORAL; Name: Supervised Aerobic Exercise; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo Pill.; Assigned to Arm(s): 3
C: Arm Label: Treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Omega-3 Fatty Acid Supplement | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Omega-3 Fatty Acid Supplement; Assigned to Arm(s): Treatment | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Referred Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard care | Arm Label: Stepped Care; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy, Drug: Sertraline, citalopram, or bupropion | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): Stepped Care | Intervention Type: DRUG; Name: Sertraline, citalopram, or bupropion; Assigned to Arm(s): Stepped Care | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Referred Care

Answer: C